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I. INTRODUCTION

P
OTENT antiretroviral inhibitors have been developed however, mono-therapy may result in drug resistant virus emergence [1] . Highly active antiretroviral therapy (HAART) is effective in prolonged reduction of virus load. Nevertheless, HIV treatment difficulties remain due to chronic virus latency. Therefore, HIV eradication via antiretroviral regimens is not possible [2] . Consequently, unlimited HAART treatment periods are required causing liver failure and nerve damage [2] - [4] . Therefore, long-term nonprogressor (LTNP) status is desired. LTNP is defined as a patient who has the virus, without symptoms of AIDS for more than seven years without treatment [5] .
Recently, it is reported structured therapy interruption (STI) can lead to LTNP [6] . STI is a treatment method that gives medication interruptions to reduce side effects or help the immune system control HIV [7] . Therefore, various methods of STI are being tested to study immune responses and virus replication [2] . STI temporarily increases viral load to emphasize CTL proliferation that can destroy infected cells [3] , [6] . However, low CD4 T-helper cell numbers and high virus load, increase risks of opportunistic infection and drug resistance [2] , [4] , [8] . Thus, virus load should not go beyond 50 copies/mL and CD4 T-helper cell count should not go below [8] . Many control methods have been reported for HIV treatment [9] - [16] . Optimal control methods were suggested considering the weighted quadratic form of drug dose and target state as performance indexes. HIV treatment methods have drawn attention from the biomedical and control engineering societies. Full treatment without schedule might result in lethal patient impairment, thus, there is need for optimal control method [9] - [11] . Feedback control methods also demonstrate greater drug efficiency [12] . Optimal control methods were successful in suppressing virus load however, mutation emergence was not considered. Recently, dynamics including continuously mutating virus were proposed and optimal control problem was solved [13] .
Previous papers are successful in total drug dosage and side effect reduction, but they do not consider CTLp that plays an important LTNP role. Recently, model-based predictive control (MPC) methods were used for constructing treatment schedules emphasizing CTLp increase [15] , [16] . Optimal scheduled treatment interruption is achieved by integrating the sum of quadratic weighted states and absolute input dosage [15] . However, both virus load and CD4 T-helper cell count are not within baselines considered in the paper. MPC use was suggested in cases involving modeling error or uncertainty [15] . Alternatively, optimal control problems can be solved with an input of continuous drug levels [16] . CD4 T-helper cell and virus load can be kept within baselines by adjusting cost function. However, continuous variation of the level of treatment increases regimen difficulty as well as drug resistance [6] , [15] .
Zurakowski et al. used a MPC-based method involving extensive numerical searches requiring one week sampling times. We present a case without ability to suppress virus load or increase CD4 T-helper counts during treatment with one week sampling time. Thus, a shorter sampling time is required for the simulation, e.g., one day. Using short sampling times gives rise to additional problems however, dynamic programming can solve constrained optimal control problems. Optimized STI reduced total drug dosage and established long-term immune response. Furthermore, CD4 T-helper cell count and virus load were kept within baselines by defining constraints and/or adjusting cost function. Recently, it is proposed medication should be initiated when controllability is relatively high. High controllability means treatment needs less control effort, implying therapy is more effective [17] , [18] . Controllability increased during each interruption. In addition, we saw that the MPC-based treatment method using dynamic programming succeeded in establishing long-term immune response, even though parametric uncertainties existed in the model. We observed gradual reduction of drug 0018-9294/$20.00 © 2006 IEEE dosage, which is suggested as an important phenomenon in optimal control on HIV therapy. Our optimized STI was more practical compared to optimal control methods of [16] . Moreover, drug resistance was avoided by constraining drug input to either full or none [6] , [15] . This paper is organized as follows. In Section II, we describe a working model with which CTLp role in LTNP is considered. Section III introduces an optimal control method used for HIV treatment and its performance in terms of controllability as well as cost function. Simulation results and analysis are presented in Section IV. Section V summarizes the paper. Then conclusion follows in Section VI.
II. WORKING MODEL
We are interested in treatment leading to LTNP patient classification. To understand CTLp role in LTNP, memory cells and effecter cells are distinguished in the dynamic model as in [19] . CTLp differentiate to Cytotoxic T Lymphocyte effectors (CTLe), which destroy the infected cell [3] , [6] . Our model is given by (1) where , , ,
, and derived from [19] . , , , , and represent uninfected CD4 T-helper cell, infected CD4 T-helper cell, virus load, CTLp, and CTLe, respectively. is the uninfected CD4 T-helper cell production rate. , , , and are natural death rate of , , and , respectively. is cleared at the rate of . is the infection rate coefficient. Precursors are generated at the rate of , and differentiate into the effectors at the rate of . Effectors kill infected cells at the rate of . Control input, , is the reverse transcriptase inhibitors (RTIs) dosage. RTI reduces infection rate by , where is the drug efficacy described in (1). The following are four equilibrium points when no treatment is applied. As this point is unstable, we are not interested in it.
The numerical values of equilibrium points are shown in Table I . As point 1 is unstable, it is impossible to return uninfected state after infected. In order words, complete eradication of virus is not possible. Therefore, the goal of treatment is to make patient LTNP. Two patients were studied. Due to infection duration and lack of treatment, virus and infected cells are dominant in patient A. Patient B virus, CTLp, and CTLe numbers are low in after extensive RTI treatment. Initial condition of patient A is . Initial condition of patient B is . The model that has desired behaviors is used to just offer proof of concept [20] . The model parameters in this paper are arbitrary and of no clinical significance. Thus, notice that the states do not correspond with any clinical measurements. Furthermore, CTLp are not usually measured explicitly [21] . They are difficult to distinguish from effectors. All CTL are usually measured as a whole, in number of cells per volume of blood. It is same with CD4 cells. Usually, no distinction is made between uninfected and infected, they just have a CD4 cell count.
III. METHODOLOGY
Shim et al. propose optimal control for continuous regimen HIV treatment. Sequential quadratic programming and projected descent methods were used for solving nonlinear dynamic equations with continuous optimal input between 0 (no treatment) and 1 (full treatment) [22] . We used a cost function (2) to reduce total drug dosage and drive the patient's status to LTNP (2) where is , is 1, and the terminal cost, , is . is the LTNP's status represented as Point 3 in Table I . However, continuously varying drug dosage may increase drug resistant mutants [6] , [15] . Thus, [15] constrained the input to either 0 or 1. Therefore, [16] methodology may not be practical. Furthermore, it is very difficult to get numerical solution to constrained optimal control with system (1) using [16] proposed methods. Additionally, sometimes viral suppression and CD4 T-helper cell maintenance was not possible using one-week sampling time. Thus, [15] methodology may fail to meet viral load and CD4 T-helper cell constraints. We will show this result in Fig. 2 (Section II-D) .
We used dynamic programming to optimize the HIV treatment regimen [23] . Each quantized state on each day had an optimal value of (either 0 or 1) for minimizing total cost. By looking at the closest quantized state from the patient's status, one could decide to administer drugs or not. Adhering to this rule allowed and to stay within each baseline. Levels of quantization for each state, , , , , and were 5, 4, 4, 6, and 4, respectively.
The continuous regimen controllability suggested in [16] and our proposed dynamic programming method were compared. Controllability is an estimate of drug efficiency within the patient. A higher minimum singular value indicates an easier to control virus load [18] . A minimum singular value controllability matrix can approximate practical controllability. System (1) could be linearized for controllability analysis such as (3) where From the linearized system (3), we computed the controllability matrix such as
We applied singular value decomposition to controllability matrix , and plotted the minimum singular value in Section IV. Refer to [18] for detailed explanation of the controllability analysis.
IV. SIMULATION RESULTS AND ANALYSIS
Patient A and B cases were simulated and results compared. Section IV-A shows dynamic programming optimized STI compared with other STI. Section IV-B shows controllability comparison between full and no treatments. Optimized STI using dynamic programming is paralleled with continuous optimal regimen in Section IV-C. The STI of [6] and [15] were named "boosting method" and "MPC-based method" respectively. , 
A. Comparison of Previously Proposed Methods and Optimized STI
System (1) was simulated for patient A and B with treatment methods suggested in [6] , [15] . Figs. 1 and 2 suggested both previously suggested methods were successful in inducing long-term nonprogression. Figs. 3 and 4 demonstrate our simulation results using dynamic programming for patient A and B respectively. Our method also achieved patient LTNP status. Our proposed method will be called, optimized STI, in which input is either one or zero. Fig. 2 demonstrates the MPC-based method suggested in [15] . Treatment interruption scheduling was optimized by searching every input sequence. The finite horizon was 91 days. Sampling time was one week. Fig. 1 shows patient A was boosted twice with interruptions, while patient B was under medication longer before the boosting method applied. Patient B's treatment was interrupted for 25 days, prior to 66 days on medication. Fig. 2 shows the MPC-based method on patient A and B giving ten interruptions each case: The sampling period is 7 days. We observed the boosting method and the MPC-based method could induce LTNP as suggested in [6] , [15] . Figs. 1 and 2 show CD4 T-helper cell count decreases below increasing opportunistic infection possibility. Furthermore, peak virus load is greater than 50, which can increase resistance [8] . 
B. Controllability Analysis
Figs. 5 and 6 indicate minimum singular values of controllability matrices for patient A and B without treatment and full treatment respectively. Figs. 5 and 6 indicate controllability estimates decrease with time under continued full treatment. Also, long duration of treatment can impair the immune system due to the low CTL concentration [24] . [17] , [18] state having higher controllability indicates more effective therapy, suggesting initial treatment delay until high controllability. Figs. 3 and 4 show patient A medication was started immediately, while medication was withheld three days for patient B respectively, during optimized STI. Both patients started medication at relatively high controllability. Additionally, we observed estimates of controllability increased during temporal treatment cessation.
C. Comparison of Continuous Optimal Control and Optimized STI Using Dynamic Programming
Figs. 7 and 8 demonstrate patients treated by continuous optimal control proposed in [16] . [16] used MPC-based optimal control with input constrained to . [16] indicates gradual drug dose reduction is the key point for enhancing CTL immune response. Figs. 3 and 4 show discrete regimens have more state variable fluctuations compared to continuous optimal regimen. However, total cost differences are within 10% as shown in Table II . Furthermore, Figs. 3, 4 , 7, and 8 show CD4-T baselines and virus load are kept. Simulation demonstrates an analogous pattern in optimal is observed, indicating a gradual drug input reduction.
Figs. 3 and 7 indicate patient A medications are initiated on day one when controllability estimates are relatively high.
Figs. 4 and 8 demonstrate both medications are initiated on day four for patient B. Note patient B's minimum singular values of controllability matrices are relatively small until the third day. We presume it is a nature of the optimal control. Besides, Fig. 7 shows optimal control with continuous input yields controllability increases days eight to forty. 
D. Robustness Against Parameter Uncertainties Using MPC
It is known that the MPC method is robust against parameter uncertainties such as un-modeled dynamics and/or measurement errors [25] , and its application to HIV treatments has been reported in [15] , [16] . To demonstrate the robustness of our proposed method, we have used the MPC method to solve the optimized STI with dynamic programming. To determine the system performance on parameter perturbation, approximately perturbations are considered ( ,
. The finite horizon is 700 days. The simulation results of using only dynamic programming in the presence of the parameter uncertainties are shown in Fig. 9 . For both patients, CTLp failed to increase and long-term immune response is not established. However, when MPC is employed, STI is successfully optimized, as shown in Fig. 10 . The total period of medication is longer than in the case without parameter uncertainties. It induces, however, long-term nonprogression while constraining the state variables within their baselines. We confirmed that LTNP can be successfully established even in the presence of parameter uncertainties. Recently, it is also reported that approximate dynamic programming strategy can reduce the amount of online computation and can be used as an alternative to MPC [26] . This method may be useful in solving more complicated optimal control problems such as models which include the dynamics of HIV mutation.
V. DISCUSSION
The proposed optimized STI established long-term immune response as previous treatment methods did. Constrained optimization problems for HIV treatment were solved, reducing the probability of opportunistic infection and resistant viral strains.
It is reported high controllability yields more effective therapy [17] , [18] . Therefore, it was proposed medication should be initiated when controllability is high. We observed drug administration at relatively high controllability, resuming again after controllability was increased during treatment interruptions. This fact supports the drug was optimally administrated. Furthermore, gradual dose reductions is similar to continuous optimal control suggested in [16] . However, our proposed method, in which input is constrained to one or zero, is more practical. Moreover, constraining the input reduces risk of drug resistant viral strains [6] , [15] . Therefore, the optimized STI control method could be used clinically.
Treatment success using dynamic programming is highly dependent on cost function definition and quantization as well as state number. Further, discussions regarding cost function definition and quantization are required. Finally, our proposed model did not include short term interruption dynamics. Additional consideration of short term interruption dynamics and drug properties is required.
VI. CONCLUSION
This paper presented dynamic programming method for reducing total drug dosage and establishing CTLp-related immune response against HIV-infection. The treatment method using dynamic programming was compared with other STI methods. We analyzed HIV-related immune system controllability for better understanding of applying optimal treatment control. We observed medication was initiated when controllability was relatively high. Furthermore, controllability increased during each interruption. The proposed method induced long-term nonprogression reduced total drug dosage while preserving high CD4 T-helper cell count and low virus load. Furthermore, optimized STI is more practical than continuous regimen by preventing drug resistance.
